The impact of pulmonary artery (PA) catheters on patient outcome has been questioned and their usage has become controversial. Meta-analysis on mortality has shown a trend for improved survival with PA catheter-guided therapy. We now perform a meta-analysis on morbidity from PA catheters in the published literature.
Controversy has surrounded the pulmonary artery (PA) catheter since its introduction into clinical practice a quarter of a century ago. Although the impact of the PA catheter on patient outcome has been questioned in several investigations, no clear conclusion has been reached. Studies addressing the efficacy of the PA catheter on various end points, such as survival, complications such as multiple organ failure and duration of intensive care unit stay have had disparate results. Some have shown a positive effect of the PA catheter; some have shown a negative effect, and some have shown no effect at all. At the same time, PA catheters continue to be widely used in medical and surgical intensive care units and operating rooms across the world.
The controversy culminated with the publication in 1996 of a large study (1) showing that patients who received a PA catheter had a higher mortality than patients who did not receive a PA catheter. Although the design of that study was not optimal (it was not randomized, the controls were casematched using a controversial propensity score, and it was retrospective), it led to an outcry in medical and lay press alike, and calls for a moratorium on the use of the PA catheter ensued.
A common problem among published studies has been a limited number of patients and participating centers. Furthermore, there have been large differences in patient populations and severity of illness. Methodologic limitations have been prevalent and most of the available work is in the form of observational and retrospective analyses. Even the few randomized and controlled trials have had some design deficiencies. For instance, these studies are impossible to blind. There have also been ethical considerations leading to problems with patient accrual and selection bias, crossover between groups, and violations of statistical assumptions. Because of the practical difficulties involved in devising a proper large multicentered trial concerning the impact of PA catheters on the outcome of the critically ill, meta-analysis of the existing data would be particularly useful. We have previously performed a metaanalysis of mortality data from randomized clinical trials that showed a nonsignificant trend toward reduced mortality in patients managed with a PA catheter (2) .
In this study, we perform a metaanalysis on morbidity as an outcome end point related to the use of PA catheters. To our knowledge, there has been no publication so far addressing this particular question.
MATERIALS AND METHODS
We conducted a literature search of the medical database through 1970, using the headings "pulmonary artery catheterization,"
"Swan-Ganz catheterization," and "right heart catheterization," and restricted the results to "effectiveness" and "usefulness." This yielded >100 original investigations of the effectiveness of PA catheters or the introduction of new patient management strategies involving the PA catheter and approximately half that number of editorials on the subject. A total of 16 randomized controlled trials were identified addressing the question of the effectiveness of PA catheters as compared with management without a PA catheter. Of these, 12 trials were found to include data on morbidity related to the use of PA catheters.
Quality scores for each study were performed by two independent reviewers using a method previously proposed by Chalmers et al. (3) and averaged. Points were awarded for different aspects of study design, including randomization, blinding, control regimens, data collection, and statistical analysis.
Morbidity data were then reviewed. Major morbidity was defined in this study as organ dysfunction. Thus, using definitions by Fry (4), Knaus and Wagner (5) , and Bone et al. (6) , organ system dysfunctions were defined.
Pulmonary system dysfunction was defined as PaO 2 /FiO 2 ≤250, intrapulmonary shunt ≥20% with normal pulmonary artery occlusion pressure, or a need for mechanical ventilation for >24 hrs.
Cardiovascular system dysfunction was defined as mean arterial pressure ≤50 mm Hg, cardiac index ≤ 2.2 L/min/m 2 , pulmonary artery occlusion pressure ≥ 18 mm Hg, or the occurrence of ventricular tachycardia or fibrillation.
Renal system dysfunction was defined as serum creatinine more than twice the preexisting value or a need for renal replacement therapy.
Hepatic system dysfunction was defined as serum bilirubin, transaminases or lactate dehydrogenase more than twice the preexisting values.
Hematologic system dysfunction was defined as white blood cell count ≤ 1,000/mm 3 , platelets ≤ 50,000/mm 3 , or prothrombin time or partial thromboplastin time ≥1.5 times control.
Gastrointestinal system dysfunction was defined as transfusion requirement of >2 units of packed red blood cells with documented stress ulceration.
Neurologic system dysfunction was defined as a Glasgow Coma Scale score ≤7 in the absence of sedation or intracranial lesions.
Sepsis was defined as the presence of identifiable infection with two or more of the following conditions: temperature >38°C (100.4°F) or <36°C (96.8°F), heart rate >90 beats/minute, respiratory rate >20 breaths/minute, PaCO 2 <32 mm Hg, and white blood cell count >12,000/mm 3 or <4,000/mm 3 , or with >10% immature neutrophils.
In the more recent studies, major morbidity was defined explicitly as organ failures described above, and those were entered directly. In some of the older studies, definitions of morbidity were considered too broad and data were revised to reflect the above. To be consistent, the morbidities not meeting the above criteria were excluded from the primary meta-analysis. The study of Schultz et al. (7) excluded complications in both groups described as "predominantly wound infections." In Isaacson's study (8) there were the following exclusions from the primary analysis: three patients with transient dysrhythmias in the control group and five in the PA catheter group, two patients with labile blood pressure in the control group and three in the PA catheter group, one patient with electrocardiographic changes in the control group, one patient with pleural effusion in each group, one patient with a transient infiltrate in the control group and one patient with bronchospasm in the PA catheter group, three patients with postoperative ileus in the control group and one patient with colitis in the PA catheter group, as well as one patient with a deep vein thrombosis in the control group. In the study by Berlauk et al. (9) , we excluded two patients with graft thrombosis (this was considered an expected postsurgical complication unrelated to the presence or absence of a PA catheter and did not qualify as an organ failure) in the PA catheter group and four similar patients in the control group. In the control group, there was also a patient with transient arrhythmia that was also excluded. From the study by Shoemaker et al. (10) , the following patients were excluded: one patient with urinary tract infection in each group, one patient with pancreatitis in each group, one patient with post-operative hemorrhage in each group, two patients in the control group and three in the PA catheter group with wound infection, one patient with an abdominal abscess in the control group, one patient with gastric outlet obstruction in the PA catheter group, one patient with evisceration in the control group, and two patients in the control group and six in the PA catheter group with pleural effusions. Finally, the following patients were excluded from the study by Boyd et al. (11) : two patients in the control group and three in the PA catheter group with radiographic pleural effusions, three patients in each group with wound infections, one patient in the control group with an abdominal abscess, eight patients in the control group and one in the PA catheter group with postoperative hemorrhage, two patients in the PA catheter group with radiographic gastric outlet obstruction, seven patients in the control group and five in the PA catheter group with "clinical chest infection," three patients in the control group and one in the PA catheter group with psychosis, four patients in the control group and two in the PA catheter group with distal ischemia, and three patients in each group with unspecified "other" complications.
To assess the risk of morbidity as defined above between the treatment and control groups for the 12 studies, twelve 2 × 2 tables were set up. For purposes of analysis, an adjustment of .5 was used to the cells in the strata where there was a zero cell. The risk was bounded to 100% if the rate of morbidity exceeded 100% (if there was more than one organ failure per patient).
To explain some of the variability between studies, a random effect model was also used on the log(RR) of the twelve studies. The random effects model was defined by the following formula: log(RR) i = μ + δ i + i , where log(RR) i was the observed log relative risk ratio in each study, μ was the mean effect for a population of possible similar trials, δ i was the deviation of the ith study's effect from the population mean, and i was the sampling error. Thus, Var( i ) was the sample variance, s i 2 , calculated from the data; μ + δ i was the true treatment effect in the ith study, and Var( δ i ) represented both the degree to which treatment effects vary across experiments as well as the degree to which individual studies give biased assessment of the treatment effects. Table 1 . Mortality data were previously reported in part in a separate meta-analysis of mortality from 16 trials (2). It is included here for easy referral. Table 1 also shows the year of publication of the separate studies, design scores, acuity of patient population, type of intensive care unit studied (surgical or medical), and type of comparison (PA catheter vs. no PA catheter, or PA catheter vs. PA catheter for supranormal values, which are higher than normal values of cardiac index and oxygen delivery, thought to possibly be desirable in the critically ill organism). Table 1 also summarized our primary end point of major morbidity as well as total complications reported (major morbidity and excluded complications). Both major morbidity and total complications were greater in the control group, although the difference is smaller for major morbidity. Meta-analysis was then performed on major morbidity as described above. Using a two-tailed test, at the alpha =.05 level, the difference in morbidity was statistically significantly lower for treatment compared with control. A relative risk ratio of 0.78074 was obtained with a 95% confidence interval of 0.6459-0.94374; those with treatment had a mean protective effect of 21.9% for risk of morbidity. The corresponding p value was .0168. The actual relative risk ratios and 95% confidence intervals are shown in Figure 1 for each study. Table 1 . Outcome data from the 12 trials Acuity, quality score, number of years elapsed since the study was published, type of comparison, and type of intensive care unit all increased variability and were not statistically significant predictors for risk ratio of morbidity (Table 2 ). Sensitivity analysis for the separate studies is presented in Figure 2 . The overall relative risk ratios and 95% confidence limits for all studies along with relative risk ratios and confidence intervals that are recomputed after each individual study has been omitted in turn from the analysis are depicted. This analysis suggests the stability of the relative risk ratio and the lack of any single influential studies. Table 2 . Results of multivariate random effects models comparing effects of possible covariates 
RESULTS

Data from the 12 trials is shown in
DISCUSSION
The principal finding of our metaanalysis is a decreased incidence of major morbidity when the data from the PA catheter is used for treatment. As explained above, we have defined major morbidity, our primary end points, as new organ failures. We elected to do that with the intent to avoid entering minor morbidities lacking clinical significance so that the data for comparison would be uniform and well defined. We did include all morbidities in Table 1 and showed the same overall trend for PA catheter-associated therapy to be associated with fewer complications.
A meta-analysis on overall mortality from PA catheters using the results of all available randomized controlled trials has been done elsewhere (2) . It was conducted in a similar fashion on the 16 identified studies and revealed a trend for improved survival and a modest risk reduction related to the use of PA catheters after controlling for the quality of the trials.
Recently, several authorities have debated the usefulness of PA catheters. This has included claims about PA catheterinduced harm (12, 13) . Because the individual studies that have formed the basis for these claims have methodologic limitations, we have chosen to investigate the question of PA catheter usefulness by performing meta-analyses on the existing literature. Both of our meta-analyses actually show that PA catheters are not harmful to patients. The meta-analysis of mortality revealed only a trend for improved survival, but the morbidity meta-analysis presented here showed a statistically significant difference in major morbidities with a reduced incidence in the PA cathetertreatment groups. The implication of these findings is that the data generated from PA catheters, when used by protocol, is useful rather than harmful and that calls for a moratorium on their usage may be premature and unnecessary.
A potential flaw of our study is that we have included only a limited number of trials in our meta-analysis, namely all available randomized controlled trials. We have done so realizing that although this would restrict the size of our database, it would make it more uniform for a more valid statistical analysis. We have also used a random effects model to account for between-study variability as described above to look at sources of heterogeneity. The use of only new organ failures as our definition of majority morbidity makes our identification of end points less bias prone. Although design issues have been raised concerning many of the original clinical trials, our results did not suggest that the design score of individual studies influenced our results. Furthermore, many of the design limitations, such as blinding, cannot be overcome.
PA catheterization is an invasive procedure and, as such, carries its own risks (14, 15) , such as pneumothorax, bleeding or thrombosis, infection, and arrhythmias. Notably, in the 1,610 patients included in our analysis, there were no major catastrophes related to PA catheter insertion and maintenance. It is possible that no such events happened, because of experienced operators, or simply that they were not reported. This raises the question of quality of reporting, a very important issue that cannot be judged objectively and may indirectly lead to another limitation of our study.
The first group of trials that we have reviewed is comprised of four somewhat older small studies comparing patients with PA catheters and patients without PA catheters. Isaacson (18) concluded that optimization of hemodynamic values was of benefit in the high-risk surgical/trauma patient, whereas Durham et al. (19) and Gattinoni et al. (20) found no benefit in high-risk surgical and mixed patient populations, respectively. Notably, the study by Gattinoni et al. (20) is by far the largest and best-designed of the cited trials. A common flaw in this group of studies is that benefit was mostly shown in the subgroups of patients who were able to achieve the goal of supranormal values whether by intentionally aggressive therapy or by conventional measures alone and no benefit was observed in the optimal treatment group patients who could not reach the goal values. Those patients, in fact, do as poorly as those control patients who were not able to attain a hyperdynamic circulatory state. For example, in both of the studies of Yu et al. (21, 22) , an overall effect of supranormal goals was not detected, statistically significant results were obtained only by posthoc analysis of subgroups. In fact, a recently published meta-analysis (23) of these trials (with the exception of the one by Durham et al.), has found no overall statistically significant mortality benefit of the interventions designed to achieve supranormal values.
